To use all functions of this page, please activate cookies in your browser.
Adjustment of drug dose for rheumatoid arthritis by diagnostic method
Determination of the therapeutic window of adalimumab
Collaboration between the Immanuel Klinikum Bernau Herzzentrum Brandenburg, the Rheumazentrum Nord-Brandenburg and BioTeZ demonstrates new ways of treating rheumatoid arthritis.
Through the introduction of therapeutic antibodies, the treatment results for rheumatoid arthritis (RA) have been significantly improved over the past decade. However, cases of inadequate effectiveness remain, as well as side effects due to the associated strong immunosuppression, especially with high activity levels. One possibility for therapy optimization is the targeted, individual dose adjustment of the active ingredients for each patient. At the moment, all RA patients treated with the TNF-alpha inhibitor adulimumab received a pre-approved standard dose of 40 mg every 14 days without regard for existing differences in body weight, sex, health status, metabolism and age. As a result, some patients receive too high drug dose and other patients have too low drug levels.
Using an ELISA-test from BioTeZ, it is now possible simultaneously quantify the concentrations of the therapeutic antibody adalimumab and the target antigen TNF alpha in the patient's serum during therapy.
A total 47% of the patients showed drug levels in the target area, leading to an effective neutralization of TNF-alpha. 35% of the patients showed low drug doses resulting in reduced TNF alpha neutralization rates under standard therapy. 18% of patients had increased drug levels and high neutralization rates. A further dose increase for these patients is neither useful nor recommended.
"If the effect of the drug is insufficient and the drug level is low, a dose increase of the adalimumab by a weekly injection can lead to a significantly better therapeutic response (Zänker et al., 2017). This is in line with our everyday experience in the clinics and has now been scientifically documented in this study", says Dr. Michael Zänker, rheumatologist and chief physician for internal medicine at Immanuel Klinikum Bernau Herzzentrum Brandenburg.
In the case of very high drug levels, as in 18% of the patients and if the therapeutic goal is achieved, there is the possibility of de-escalating the therapy, by stretching the interval of the injections by several days. Thus the amount of active substance in the patient can be reduced to the recommended values, while avoiding possible side effects as well as reducing treatment costs.
"The results contribute to the individual treatment of patients with rheumatoid arthritis and are an important add on to the therapy prediction of anti-TNF-alpha monotherapy with adalimumab" so, Dr. Janko Brand, scientific director of the study at BioTeZ.
The study was funded by the Rheumazentrum Nordbrandenburg e.V. The results of more elaborated studies are currently being evaluated and new customer projects for further biologics are being developed.
- bioavailability
- side effects
- drug-induced side effects
- active ingredients
- therapeutic window
-
News
Progress in Super-Resolution Microscopy
Does expansion microscopy deliver true-to-life images of cellular structures? That was not sure yet. A new publication shows for the first time that the method actually works reliably. Immersing deeper and deeper into cells with the microscope. Imaging the nucleus and other structures more ... more
Nobel Prize for Physics 2018 announced
The researchers Arthur Ashkin and Gérard Mourou and Donna Strickland were announced today as this year's winners of the Nobel Prize for Physics. Their achievements in the field of laser physics was groundbreaking and worthy of the Nobel Prize Committee's appreciation. The discovery of optic ... more
How well do we understand the relation between incorrect chromosome number & cancer?
Over a century ago, a German-born scientist experimenting with impregnated sea urchin eggs had an insight that led to one of the first modern theories of cancer. Theodor Boveri linked incorrect chromosome number in urchin embryos with abnormal development. In 1902 he reasoned that having th ... more
-
Publications
[Research Article] Laser spectroscopy of muonic deuterium
The deuteron is the simplest compound nucleus, composed of one proton and one neutron. Deuteron properties such as the root-mean-square charge radius rd and the polarizability serve as important benchmarks for understanding the nuclear forces and structure. Muonic deuterium μd is the exotic ... more
Monkey neurophysiology to clinical neuroscience and back again [Neuroscience]
Gustav Theodor Fechner defined the field of psychophysics as the study of the relationship between the physical properties of stimuli and the internal responses or perceptions they evoke. Since the mid-19th century, psychophysics has evolved into a very powerful field of study exploring the ... more
[Perspective] A tree of the human brain
Every cell of your body was generated by cell division, forming a lineage tree that goes back to the fertilized egg. Mutations are introduced by errors in DNA replication at every cell division, as well as by mutational processes that operate continuously, such as exposure to ultraviolet li ... more
-
Research Institutes
Max-Planck-Institut für Quantenoptik
Research at the Max Planck Institute of Quantum Optics concentrates on the interaction of light and matter under extreme conditions. One focus is the high-precision spectroscopy of hydrogen. In the course of these measurements Prof. Theodor W. Hänsch developed the frequency comb technique f ... more
-
Associations
Deutsche Gesellschaft für Rheumatologie e.V.
Veranstaltungen more
- 1Designer cytokine makes paralyzed mice walk again
- 2New ion trap to create the world's most accurate mass spectrometer
- 3COVID-19 has multiple faces
- 4A prognostic Alzheimer’s disease blood test in the symptom-free stage
- 5Detect neurodegenerative diseases such as Alzheimer's by a simple eye scan?
- 6New and highly efficient method for SARS-CoV-2 mutation analysis
- 7Nanocrystals that eradicate bacteria biofilm
- 8Why remdesivir does not fully stop the coronavirus
- 9Detecting COVID-19 antibodies in 10-12 seconds
- 10Single-cell test can reveal precisely how drugs kill cancer cells
- Opening the way for global innovation in biotechnology
- GLOBAL BIOENERGIES and AUDI continue partnership in renewable gasoline
- Developing drugs to treat Parkinson’s disease
- Jacobs University and Fraunhofer IME signed collaboration agreement
- Stora Enso enters into strategic partnership with Swedish University of Agri ...